Justin Y. K. Tang

https://assets.montefioreeinstein.org/profiles/images/physphoto/Tang_Justin_MD_420x504.jpg

First Name

Justin

Last Name

Tang

NPI

1619385747

Faculty ID

16500

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

56697

Is Open Scheduling

Off

Stuart Packer

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/0d90dcb0-3939-11ed-9b41-f32856b0701a.jpg

First Name

Stuart

Last Name

Packer

NPI

1124059621

Faculty ID

13484

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Stuart Packer, MD, is a medical oncologist with extensive experience in treating lung, head and neck, prostate and other types of cancer. After graduating magna cum laude from Case Western Reserve University, Dr. Packer received his medical degree from the State University of New York/Downstate Medical Center. He went on to complete a residency in medicine and fellowship in hematology/medical oncology at Duke University Medical Center. Since then Dr. Packer has held clinical and teaching positions at leading cancer centers, including Memorial Sloan-Kettering Cancer Center, Mount Sinai School of Medicine and Montefiore Einstein Center for Cancer Care.</p>
<p>Dr. Packer&rsquo;s clinical expertise is in medical management of lung cancer, head and neck cancer and prostate cancer. He is director of the melanoma and sarcoma programs at Montefiore Einstein Center for Cancer Care. In addition, Dr. Packer is medical director of Montefiore&rsquo;s Oncology Care Model (OCM), an alternative payment model sponsored by the Centers for Medicare and Medicaid Services and aimed at improving patient care coordination and appropriateness of care.</p>
<p>Dr. Packer is the author or co-author of medical textbook chapter and articles in peer-reviewed journals, including <em>Cancer, Clinical Cancer Research, British Medical Journal</em> and <em>Lung Cancer</em>. He is a member of the American Society of Clinical Oncology and the American Society of Hematology.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Packer&rsquo;s clinical expertise is in medical management of lung cancer, head and neck cancer and prostate cancer.

Elsevier Profile

EMR ID

5497

Biography

<p>Stuart Packer, MD, is a medical oncologist with extensive experience in treating lung, head and neck, prostate and other types of cancer. After graduating magna cum laude from Case Western Reserve University, Dr. Packer received his medical degree from the State University of New York/Downstate Medical Center. He went on to complete a residency in medicine and fellowship in hematology/medical oncology at Duke University Medical Center. Since then Dr. Packer has held clinical and teaching positions at leading cancer centers, including Memorial Sloan-Kettering Cancer Center, Mount Sinai School of Medicine and Montefiore Einstein Center for Cancer Care.</p><p>Dr. Packer&rsquo;s clinical expertise is in medical management of lung cancer, head and neck cancer and prostate cancer. He is director of the melanoma and sarcoma programs at Montefiore Einstein Center for Cancer Care. In addition, Dr. Packer is medical director of Montefiore's Oncology Care Model (OCM), an alternative payment model sponsored by the Centers for Medicare and Medicaid Services and aimed at improving patient care coordination and appropriateness of care.</p><p>Dr. Packer is the author or co-author of medical textbook chapter and articles in peer-reviewed journals, including <em>Cancer</em>, <em>Clinical Cancer Research</em>, <em>British Medical Journal</em> and <em>Lung Cancer</em>. He is a member of the American Society of Clinical Oncology and the American Society of Hematology.</p>

Is Open Scheduling

Off

Thomas J. Ow

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/710fa3e0-f990-11ec-b0e5-33df62dd05e0.jpg

First Name

Thomas

Last Name

Ow

NPI

1891094850

Faculty ID

13476

CMO Specialties

Clinical Terms

Employment Status

Voluntary

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p><strong>Overview</strong></p>
<p>Dr. Ow is a Head and Neck Surgeon and Translational Researcher at Montefiore Medical Center-Albert Einstein College of Medicine.&nbsp; He specializes in the surgical treatment of&nbsp;tumors in the head and neck region, including&nbsp;those that occur in the mouth, throat, larynx, neck,&nbsp;sinuses, salivary glands, and thyroid gland.&nbsp;&nbsp;He also specializes in the&nbsp;surgical treatment&nbsp;of skin cancers&nbsp;that occur on&nbsp;the scalp, face, and neck.&nbsp;</p>
<p>Dr. Ow&rsquo;s research is focused on the translation of genetic and molecular determinants in&nbsp;head and neck squamous cell cancer&nbsp;into clinically useful biomarkers and therapeutic targets.&nbsp; Specifically, Dr. Ow is studying factors that contribute to radiation and chemotherapy resistance in this disease, as well as genomic alterations acquired during the process of locoregional recurrence, lymph node spread, and distant metastasis.&nbsp; As a translational scientist, Dr. Ow is involved in active projects&nbsp;studying&nbsp; laboratory models of HNSCC, research utilizing patient's tumors, as well as clinical research - both retrospective studies and prospective clinical trials.&nbsp; The ultimate goal of this work is to identify novel ways to improve the survival and functional outcomes among patients with HNSCC.&nbsp;</p>
<p><strong>Institutional, Regional, and National Roles</strong></p>
<div><span style="font-size: 14px;">Vice Chair, Protocol Review and Monitoring Committee, Alber Einstein Cancer Center</span></div>
<div>&nbsp;</div>
<div><span style="font-size: 14px;">Director of Clinical and Translational Research,&nbsp;</span></div>
<div><span style="font-size: 14px;">Department of Otorhinolaryngology-Head and Neck Surgery</span></div>
<div><span style="font-size: 14px;">Montefiore Medical Center/Albert Einstein College of Medicine</span></div>
<div>&nbsp;</div>
<div><span style="font-size: 14px;">Member Head and Neck Surgery and Oncology Committee, AAO-HNS</span></div>
<div>&nbsp;</div>
<div><span style="font-size: 14px;">Vice-Chair, Cutaneous Malignancy Section, American Head and Neck Society</span></div>
<div>&nbsp;</div>
<div><span style="font-size: 14px;">Treasurer, New York Head and Neck Society</span></div>
<div>&nbsp;</div>

Research Areas

Research Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Clinical focus is on the surgical treatment of tumors in the head and neck region, including those that occur in the mouth, throat, larynx, sinuses, salivary glands, and thyroid gland.<quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Dr. Ow's research focuses on the translation of genetic and molecular features of head and neck squamous cell cancer into clinically useful biomarkers and therapeutic targets.<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

PubMed.gov URL

EMR ID

4733

Biography

<p>Thomas J. Ow, MD, is Associate Professor, Otorhinolaryngology&ndash;Head and Neck Surgery and Pathology at Montefiore Einstein. He is also Director, Clinical and Translational Research for the ORL-HNS department and Vice Chair, Protocol Review and Monitoring Committee for the Montefiore Einstein Cancer Center. His clinical focus is on the surgical treatment of tumors in the head and neck region, including those that occur in the mouth, throat, larynx, sinuses, salivary glands and thyroid gland. He also specializes in the surgical treatment of skin cancers that occur on the scalp, face and neck.</p><p>After obtaining his Bachelor of Arts in biology in 2000 at Lawrence University, Dr. Ow earned his Doctor of Medicine at Northwestern University, Feinberg School of Medicine in 2004. He completed a general surgery internship at Beth Israel Medical Center in 2005, and subsequently completed his residency in otolaryngology-head and neck surgery at Montefiore Einstein in 2009. He then completed a research and clinical fellowship in head and neck surgical oncology at the University of Texas from 2009 to 2012. During this time he obtained a Master of Science in biomedical sciences at the University of Texas, Health Science Center. As a faculty member at Montefiore Einstein since 2012, Dr. Ow was both a Paul Calabresi K12 scholar in Oncology Research, and a graduate of the National Institute of Health Clinical and Translational Science Award (NIH-CTSA) sponsored Clinical Research Training Program.</p><p>Dr. Ow is both an active head and neck surgical oncologist, and translational investigator. His research is focused on the translation of genetic and molecular determinants in head and neck squamous cell cancer into clinically useful biomarkers and therapeutic targets. Specifically, Dr. Ow is studying factors that contribute to radiation and chemotherapy resistance in this disease, as well as genomic alterations acquired during the process of locoregional recurrence, lymph node spread, and distant metastasis. As a translational scientist, Dr. Ow is involved in active projects studying laboratory models of head and neck squamous cell carcinomas (HNSCC), research utilizing patient's tumors, as well as clinical research &mdash; both retrospective studies and prospective clinical trials. The ultimate goal of this work is to identify novel ways to improve the survival and functional outcomes among patients with HNSCC. His work has been published in a number of journals, books and review articles. It has also been presented internationally. His research has been supported by several institutional awards, national foundation awards, and the NIH.</p><p>Dr. Ow is board certified by the American Board of Otolaryngology and is a member of numerous professional societies, including the American College of Surgeons, the American Head and Neck Society (AHNS), the American Academy of Otolaryngology &ndash; Head and Neck Surgery, the Head and Neck Surgery and Oncology Committee (AAO-HNS) and the American Association for Cancer Research. Dr. Ow is currently Treasurer of the New York Head and Neck Society and Vice Chair of the Cutaneous Malignancy Section of the AHNS.</p>

Is Open Scheduling

Off

Vikas Mehta

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/3e9e8d00-d180-11ec-9da9-9ba17d3b79f4.jpg

First Name

Vikas

Last Name

Mehta

NPI

1902097108

Faculty ID

15233

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Clinical Focus

Clinical focus is on the treatment of patients with head and neck cancer, diseases of the salivary glands and thyroid/parathyroid disease, with a particular interest in transoral robotic surgery and minimally invasive endocrine surgery.<quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Currently, Dr. Mehta is interested in researching the clinical outcomes in head and neck cancer patients, and patients with thyroid conditions, looking particularly at health disparities, cost-effectiveness, quality of care and systems improvements.<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

EMR ID

68577

Biography

<p>Vikas Mehta, MD, MPH, FACS, is the Vice Chair and an Associate Professor in the Department of Otorhinolaryngology-Head & Neck Surgery at Montefiore Einstein. His clinical focus is on the treatment of patients with head and neck cancer, diseases of the salivary glands and thyroid/parathyroid disease, with a particular interest in transoral robotic surgery and minimally invasive endocrine surgery.</p><p>Dr. Mehta received his Bachelor of Science in Molecular Cell Biology at the University of California Berkeley in 2001. In 2006, he received his Doctor of Medicine at the University of California Irvine. Dr. Mehta completed an internship in general surgery at St. Vincent&rsquo;s Catholic Medical Center in 2007. He then completed a residency in otolaryngology at the New York Eye and Ear Infirmary. In 2012, he completed a fellowship in Head and Neck Surgical Oncology at the University of Pittsburgh Medical Center. He also attended Johns Hopkins University where he received his Master of Public Health in 2015.</p><p>Currently, Dr. Mehta is interested in researching the clinical outcomes in head and neck cancer patients, and patients with thyroid conditions, cost-effectiveness, quality of care and systems improvements. He also serves as the Quality Improvement Coordinator for the Montefiore Einstein Cancer Committee and received a green belt in Lean Six Sigma training in 2022. His previous work on a range of topics has been published in many peer-reviewed journals and books, as well as presented nationally and internationally.</p><p>Dr. Mehta is a member of numerous professional societies, including the American Head and Neck Society, the American College of Surgeons, the American Academy of Otolaryngology-Head and Neck Surgery and the New York Head and Neck Society. He maintains active board certification with the American Board of Otolaryngology.</p>

Is Open Scheduling

Off

Keyur J. Mehta

https://assets.montefioreeinstein.org/profiles/images/physphoto/Mehta_Keyur_MD_420x504-2.jpg

First Name

Keyur

Last Name

Mehta

NPI

1235339326

Faculty ID

12249

CMO Specialties

Clinical Terms

Employment Status

Voluntary

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

4466

Is Open Scheduling

Off

Shalom Kalnicki

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/89820450-b883-11ee-8618-fda8dc77c52b.jpg

First Name

Shalom

Last Name

Kalnicki

NPI

1942381371

Faculty ID

9551

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Kalnicki, a radiation oncologist, focuses on new technologies in the radiation treatment of cancer. He was a pioneer in the use of intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT), target motion management with 4-D radiation planning, and functional tumor imaging with PET-CT (positron emission tomography &ndash; CAT scan) fusion techniques. Another area of interest is the use of stereotactic guidance in radiation treatment, specifically for stereotactic radiosurgery (SRS). All enhance precision of tumor targeting with radiation therapy, increasing dose to the tumor, while sparing surrounding normal tissues.<br />&nbsp;<br />Dr. Kalnicki's research has implications for radiation treatment planning and techniques used for most clinical situations in radiation oncology, including brain, head and neck, thoracic, upper abdominal and pelvic malignancies. His clinical interests focus on head and neck, prostate, and breast cancers.</p>

Specialties

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Kalnicki focuses on researching and implementing new technologies in the radiation treatment of cancer, with the aim of enhancing the dose to the tumor target while preserving normal tissues from radiation injury, potentially increasing tumor control and improving quality of life. His research has implications for radiation treatment planning and techniques used for most clinical situations in radiation oncology, including brain, head and neck, thoracic, upper abdominal and pelvic malignancies.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Radiation Oncology

Research Focus

An active researcher, Dr. Kalnicki is currently investigating innovative methods of radiation planning and delivery, including Intensity Modulated Radiation Therapy (IMRT), PET-CT fusion for radiation planning, 4-D treatment planning, target motion manage

Elsevier Profile

EMR ID

4214

Biography

<p>Dr. Kalnicki focuses on researching and implementing new technologies in the radiation treatment of cancer, with the aim of enhancing the dose to the tumor target while preserving normal tissues from radiation injury, potentially increasing tumor control and improving quality of life. He pioneered the use of intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT), target motion management with 4-D radiation planning, stereotactic body radiation therapy (SBRT) and functional tumor imaging with PET-CT (positron emission tomography &ndash; CAT scan) fusion techniques. His research has implications for radiation treatment planning and techniques used for most clinical situations in radiation oncology, including brain, head and neck, thoracic, upper abdominal and pelvic malignancies.</p><p>Dr. Kalnicki earned his medical degree at the University of Sao Paulo Medical School in Sao Paulo, Brazil. He completed his residency and fellowship in radiotherapy at Montefiore and Albert Einstein College of Medicine. He came to Montefiore and Einstein from the University of Pittsburgh, School of Medicine, where he was Vice Chairman for Clinical Affairs and Director of Radiation Oncology at the University of Pittsburgh Cancer Institute. </p><p>Prior to joining the University of Pittsburgh Cancer Institute, Dr. Kalnicki served as Chairman of the Department of Radiation Oncology at Allegheny University of Health Sciences in Pittsburgh. He is a member of many prominent professional societies. He has authored numerous articles and abstracts during his career and is a recipient of several awards, including the Fellowship Award from the American College of Radiation Oncology.</p>

Is Open Scheduling

Off

Rafi Kabarriti

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/05986ec0-4373-11ee-9d6f-374ce67539f5.jpg

First Name

Rafi

Last Name

Kabarriti

NPI

1811200256

Faculty ID

15596

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Rafi Kabarriti, MD, is a cum laude graduate of Columbia University with a bachelor&rsquo;s degree in biochemistry and economics.&nbsp;&nbsp;He earned his medical degree at Albert Einstein College of Medicine and completed an internship in internal medicine at Mount Sinai St. Luke's and Mount Sinai West Hospital and a residency in radiation oncology at Montefiore Medical Center, where he was chief resident in the Department of Radiation Oncology.&nbsp;&nbsp;Dr. Kabarriti is the recipient of the prestigious American Society of Clinical Oncology and Conquer Cancer Foundation Young Investigator Award, Empire Clinical Research Investigator Program Fellowship and AIDS Malignancy Consortium fellowship Award.&nbsp;&nbsp;He is also funded by the NIH K12 Paul Calabresi Career Development Award for Clinical Oncology.&nbsp;&nbsp;His research has been selected for oral presentations at national and international meetings including the annual meetings of the American Society for Radiation Oncology, European Society for Radiotherapy, and the European ORL-HNS Congress. Dr. Kabarriti is author and co-author of over 40 articles published in peer-reviewed journals including the Journal of Clinical Oncology, International Journal of Radiation Oncology, Biology, and Physics, Oral Oncology and Head and Neck.&nbsp;His research focus is on optimizing radiation therapy for head and neck and gastrointestinal cancers and combining radiation therapy with novel therapeutics and immunotherapy to improve outcomes for these patients.&nbsp;&nbsp;He is the principal investigator of multiple clinical trials including investigator-initiated clinical trials as well as the local PI on cooperative and international studies.&nbsp;&nbsp;&nbsp;</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Treatment of head and neck, gastrointestinal and other cancer types, and use of advanced technologies in radiation oncology including image guidance, stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS).

Research Focus

Novel therapeutics for the monitoring and management of radiation-induced toxicities using the liver as a model; Integration of radiation therapy with immunotherapy agents to produce a strong anti-tumor systemic immune response.

Elsevier Profile

Selected Publications

<h3>Selected Publications:</h3>
<p>1. &nbsp;<strong>Kabarriti, R</strong>. Ohri, N. Hannan, R. Tishbi, N.&nbsp;Baliga, S. McGovern, KP. Mourad, WF.&nbsp;Ghavamian, R. Kalnicki, S. Guha, C. Garg, MK. PSA Decline During Salvage Radiation Therapy Following Prostatectomy Is Associated With Reduced Biochemical Failure.&nbsp;&nbsp;Practical Radiation Oncology, 2014 Feb 21. &nbsp;</p>
<p>2.&nbsp;&nbsp;<strong>Kabarriti, R</strong>. Guha, C. Hedgehog Signaling and Radiation Induced Liver Injury: A Delicate Balance.&nbsp;&nbsp;Hepatology International, 2014 Jul;8(3):316-20.</p>
<p>3.&nbsp;&nbsp;<strong>Kabarriti R</strong>, Mark D, Fox J, Kalnicki S, Garg MK.&nbsp;Proton therapy for the treatment of pediatric head and neck cancers: A review. Int J Pediatr Otorhinolaryngol. 2016 Jan;79(12)</p>
<p>4. &nbsp;<strong>Kabarriti R</strong>, Quinn TJ, Ewart MR, Mehta KJ, Lomita C, Geller DS, Kalnicki S, Fox JL. Neoadjuvant radiation therapy for the management of myoepithelial carcinoma of the upper extremity. Int J Cancer. 2018 Feb 15;142(4), PMCID: PMC6200873</p>
<p>5.&nbsp;&nbsp;<strong>Kabarriti R</strong>, Bontempo A, Romano M, McGovern KP, Asaro A, Viswanathan S, Kalnicki S, Garg MK. The Impact of Dietary Regimen Compliance on Outcomes for HNSCC Patients Treated with Radiation Therapy. Supportive Care in Cancer, 2018 Sep;26(9):3307-3313; PMID: 29671062</p>
<p>6. &nbsp;Ohri N,&nbsp;<strong>Kabarriti R</strong>, Kaubisch A, Guha C. RFA versus SBRT for HCC: Caution when Interpreting Observational Data; Journal of Clinical Oncology, 2018 Aug 20;36(24):2558; PMID: 29945527</p>
<p>7. &nbsp;Baliga S*,&nbsp;<strong>Kabarriti R*</strong>, Jiang J, Mehta V, Guha C, Kalnicki S, Smith RV, Garg, MK. Utilization of Transoral Robotic Surgery (TORS) in Patients with Oropharyngeal Squamous Cell Carcinoma and its impact on Survival and use of Chemotherapy.&nbsp;&nbsp;Oral Oncology, 2018 Nov;86:75-80; PMID: 30409323&nbsp;&nbsp;&nbsp;*co-first author</p>
<p>8. &nbsp;Brodin NP,&nbsp;<strong>Kabarriti R</strong>, Pankuch M, Schechter CB, Gondi V, Kalnicki S, Guha C, Garg MK, Tom&eacute; WA.&nbsp;&nbsp;A Quantitative Clinical Decision-support Strategy Identifying Which Oropharyngeal Head and Neck Cancer Patients may Benefit the Most from Proton Radiation Therapy. Int J Radiat Oncol Biol Phys. 2018 Nov 26.&nbsp;&nbsp;PMID: 30496877</p>
<p>9. &nbsp;Barahman M, Asp P, Roy-Chowdhury N, Kinkhabwala M, Roy-Chowdhury J,&nbsp;<strong>Kabarriti R</strong>, Guha C.&nbsp;&nbsp;Hepatocyte Transplantation: Quo Vadis? Int J Radiat Oncol Biol Phys. 2018 Nov 29.&nbsp;&nbsp;PMID: 30503786</p>
<p>10.&nbsp;&nbsp;<strong>Kabarriti R</strong>, Brodin NP, Lundgren G, Ohri N, Tom&eacute;, WA, Kalnicki S, Garg MK. Early Response Assessment on Mid-Treatment CT Predicts Loco-Regional Recurrence in Oropharyngeal Cancer Patients Treated with Definitive Radiation Therapy. Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):1036-1045; PMID: 29779936</p>
<p>11.&nbsp;<strong>Kabarriti R</strong>, Baliga S, Ohri N, Guha C, Kalnicki S, Garg, MK. Radiotherapy for Patients With Newly Diagnosed Metastatic Head and Neck Squamous Cell Carcinoma.&nbsp;&nbsp;Head and Neck, 2018 Dec 16.&nbsp;&nbsp;PMID: 30556318</p>
<p>12. &nbsp;Barahman M, Zhang W, Yaffe Harris H, Aiyer A,&nbsp;<strong>Kabarriti R</strong>, Kinkhabwala M, Roy-Chowdhury N, Beck AP, Scanlan TS, Roy-Chowdhury J, Asp P, Guha C. Radiation-primed hepatocyte transplantation in murine monogeneic dyslipidemia normalizes cholesterol and prevents atherosclerosis.&nbsp;&nbsp;J Hepatol. 2019 Jan 14.&nbsp;&nbsp;PMID: 30654068</p>
<p>13.&nbsp;&nbsp;<strong>Kabarriti R</strong>, Brodin NP, Ahmed S, Vogelius I, Guha C, Kalnicki S, Tom&eacute; WA, Garg MK.&nbsp;&nbsp;Origin of Locoregional Recurrences After Definitive Intensity-modulated Radiation Therapy (IMRT) for Laryngeal Cancer Determined Based on Follow-up PET/CT Imaging.&nbsp;&nbsp;Cureus. 2019 Jan 8;11(1):e3856; PMID: 30899607</p>
<p>14. &nbsp;Jiang JM, Ohri N, Tang J, Moadel R, Cynamon J, Kaubisch A, Kinkhabwala M, Garg MK, Guha C,&nbsp;<strong>Kabarriti R</strong>.&nbsp;&nbsp;Centers with More Therapeutic Modalities are Associated with Improved Outcomes for Patients with Hepatocellular Carcinoma.&nbsp;&nbsp;Journal of Gastrointestinal Oncology, 2019 Jun;10(3):546-553. PMID: 31183206</p>
<p>15.&nbsp;&nbsp;<strong>Kabarriti R</strong>, Brodin NP, Ohri N, Narang R, Huang R, Chuy JW, Rajdev LN, Kalnicki S, Guha C, Garg MK.&nbsp;&nbsp;Human Papillomavirus, Radiation Dose and Survival of Patients with Anal Cancer. Acta Oncolgica, 2019 Jul 8:1-7, PMID: 31282249</p>
<p>16. &nbsp;Zhu S, Brodin NP, English K, Ohri N, Chuy JW, Rajdev LN, Narang R, Kalnicki S, Guha C, Garg MK,&nbsp;<strong>Kabarriti R. &nbsp;</strong>Comparing Outcomes Following Total Neoadjuvant Therapy and Following Neoadjuvant Chemoradiation Therapy in Patients with Locally Advanced Rectal Cancer.&nbsp;EClinicalMedicine, in Press</p>

EMR ID

54490

Biography

<p class="MsoNormal">Rafi Kabarriti, MD, is a cum laude graduate of Columbia University with a bachelor&rsquo;s degree in biochemistry and economics.</p><p class="MsoNormal">Dr. Kabarriti earned his medical degree at Albert Einstein College of Medicine and completed a residency in internal medicine at St. Luke&rsquo;s-Roosevelt Hospital Center and a residency in radiation oncology at Montefiore Medical Center, where he was chief resident in the Department of Radiation Oncology.</p><p class="MsoNormal">Dr.Kabarriti is the recipient of the 2014 Young Investigator Award given by the Conquer Cancer Foundation and the American Society of Clinical Oncology. In addition, his abstracts have been selected for oral presentations at national and international meetings including the annual meetings of the American Society for Radiation Oncology. Dr. Kabarriti is author and co-author of articles published in peer-reviewed journals including <i>the International Journal of Radiation Oncology</i><i>&bull;Biology</i><i>&bull;Physics</i>, <i>Hepatology International</i>, and <i>PLoS One</i>.</p>

Is Open Scheduling

Off

Hilda Haynes-Lewis

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/e7712260-3933-11ed-9b41-f32856b0701a.jpg

First Name

Hilda

Last Name

Haynes-Lewis

NPI

1306927736

Faculty ID

15628

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Clinical Type

Nurse Practitioner

EMR ID

9852

Is Open Scheduling

Off

Balazs Halmos

https://assets.montefioreeinstein.org/profiles/images/Halmos_Balazs_MD_2x.jpg

First Name

Balazs

Last Name

Halmos

NPI

1013933290

Faculty ID

14771

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Balazs Halmos, MD, MS was recruited in May 2015 to serve as Director of the Multidisciplinary Thoracic Oncology Program and Director of the Section of Thoracic Medical Oncology for Montefiore Health Systems. Dr. Halmos has also been appointed as the first Director of Clinical Cancer Genetics and Professor of Clinical Medicine at Einstein.</p>
<p>Dr. Halmos is an authority in the management of patients with malignancies of the thoracic cavity such as lung cancer, gastroesophageal cancer and thymoma. His research interests are focused on studies of targeted agents for the treatment of thoracic malignancies as well as translational studies aimed at different aspects of lung cancer biology such as oncogenic tyrosine kinase targeting, resistance to chemotherapy, radiation and targeted therapeutics. He will oversee the thoracic clinical trials program and spearhead the effort to develop guidelines for genetic testing for cancer patients of different anatomic sites to implement a personalized cancer medicine approach.</p>
<p>Dr. Halmos joined Montefiore and Einstein from Columbia University Medical Center, where he was Director of Thoracic Medical Oncology since 2009, Associate Professor of Medicine, and Chairman of the Cancer IRB. He completed a medical degree summa cum laude from Semmelweis University in Budapest, Hungary, an internal medicine residency at St.Luke&rsquo;s-Roosevelt Hospital/Columbia University, and a hematology/oncology fellowship program at Beth Israel Deaconess Medical Center/Harvard Medical School, where he also obtained a master of science in clinical sciences from Harvard Medical School. Since completion of his fellowship, he has been on the faculties at Harvard, Case Western Reserve University, and Columbia.</p>
<p>Dr. Halmos is the recipient of multiple awards from organizations such as the American Society of Clinical Oncology, American Association for Cancer Research, and American Cancer Society and serves as a permanent review board member for the American Cancer Society. He is board certified in internal medicine and medical oncology.</p>

Research Areas

Specialties

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Halmos is an authority in the management of patients with malignancies of the thoracic cavity such as lung cancer, gastroensophageal cancer and thymoma. His research interests are focused on studies of targeted agents for the treatment of thoracic malignancies as well as translational studies aimed at different aspects of lung cancer biology such as oncogenic tyrosine kinase targeting, resistance to chemotherapy, radiation and targeted therapeutics. He oversees the thoracic clinical trials program and spearheads the effort to develop guidelines for genetic testing for cancer patients of different anatomic sites to implement a personalized cancer medicine approach.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Halmos is a thoracic medical oncologist focused on the management of patients with malignancies of the thoracic cavity, such as lung and gastroesophageal cancers as well as thymoma. He also oversees the thoracic clinical trials program of novel clinical studies at the Albert Einstein Cancer Center and is spearheading the effort to develop a molecular testing paradigm for cancer patients managed within the Montefiore Health System to facilitate a personalized cancer medicine approach throughout the health system.

Research Focus

Dr. Halmos&rsquo; research interests encompass clinical studies of experimental therapeutics, in particular studies of targeted agents for the treatment of thoracic malignancies as well as translational studies focused on different aspects of lung cancer biology, such as oncogenic tyrosine kinase targeting, resistance to chemotherapy, radiation and targeted therapeutics.

Elsevier Profile

EMR ID

33129

Biography

<p>Balazs Halmos, MD received his medical degree summa cum laude from Semmelweis University in Budapest, Hungary. He completed an internal medicine residency program at St.Luke&rsquo;s-Roosevelt Hospital/Columbia University in New York City followed by a hematology/oncology fellowship program at Beth Israel Deaconess Medical Center/Harvard Medical School in Boston, Massaschuestts.</p><p>While in Dr. Halmos, also obtained an MS degree in Clinical Sciences from Harvard Medical School. Since completion of his fellowship, he has been a faculty member at Harvard, Case Western Reserve University and most recently an Associate Professor of Medicine at Columbia University Medical Center in New York. There he served as Director of Thoracic Oncology from 2009-2014 and was also Chair of the Cancer IRB.</p><p>Dr. Halmos also oversees the thoracic clinical trials program of novel clinical studies at the Montefiore Albert Einstein Cancer Center and is spearheading the effort to develop a molecular testing paradigm for cancer patients managed within the Montefiore to facilitate a personalized cancer medicine approach throughout the health system.</p><p>He is the recipient of multiple awards from prestigious organizations such as the American Society of Clinical Oncology, American Association for Cancer Research and the American Cancer Society, where he also serves as a permanent review board member. </p>

Is Open Scheduling

Off

Madhur K. Garg

https://assets.montefioreeinstein.org/profiles/images/8782-madhur-garg.jpg

First Name

Madhur

Last Name

Garg

NPI

1215018643

Faculty ID

8782

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<dl id="header_01" class="detail">
<dd id="biography">
<p>Dr. Garg is the Clinical Director of Radiation Oncology, Director of Montefiore-Einstein's Proton Therapy Program and Co-Director of Stereotactic Radiation Therapy Program at Montefiore Medical Center.</p>
<p>He earned his medical degree at King George&rsquo;s Medical College and completed his residency in radiation oncology at Rush-Presbyterian-St. Luke&rsquo;s Hospital in Chicago and Montefiore in New York City. He also completed a specialized fellowship at Wayne State University in Detroit.</p>
<p>Dr. Garg is the recipient of the prestigious American Society of Clinical Oncology&rsquo;s Young Investigator's Award and the Department of Defense Physician Research Award. He is listed as one of the &ldquo;New York Top Doctors,&rdquo; &ldquo;America&rsquo;s Top Oncologists&rdquo; and &ldquo;Best Doctors in America.&rdquo;</p>
<p>Dr. Garg serves on several Montefiore and Einstein committees, as well as international societies such as the American Society of Clinical Oncology, the American College of Radiology and the American Society for Radiation Oncology. He is on the review boards for several journals, including&nbsp;<em>International Journal of Radiation Oncology &bull; Biology &bull; Physics</em>.</p>
<p>Dr. Garg is a principal investigator of several national and international research studies involving novel cancer treatment modalities and is actively involved in quality of life and healthcare issues for cancer patients.</p>
<p>His areas of interest are as below:</p>
</dd>
</dl>
<p>1. Advanced Technologies in Radiation Oncology (IMRT and IGRT)</p>
<p>2. Stereotactic Radiosurgery (SRS) for brain and spinal cord tumors</p>
<p>3.Proton Therapy and Particle Therapy</p>
<p>4. Stereotactic Body Radiation Therapy (SBRT) for lung and liver malignancies</p>
<p>5. Functional imaging and adaptive planning for Head/Neck malignancies</p>
<p>6. Translational research involving role of Anti-Angiogenensis and Immunotherapy in radiation therapy</p>
<p>7. Addressing Disparties in Cancer Care</p>
<p>8. Diet, Nutrition and Cancer</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Advanced technologies in radiation oncology with a focus on stereotactic targeting, functional imaging and adaptive planning.

Research Focus

Translational research involving anti-angiogenesis and radiosensitivity. Dr. Garg is a principal investigator of several national and international research studies involving novel cancer treatment modalities and is actively involved in quality of life for cancer patients.

Elsevier Profile

Selected Publications

<p><strong>1. Garg MK</strong>, Tekyi-Mensah S, Bolton S, Velasco J, Pontes E, Wood Jr DP, Porter AT, Forman JD: <em>The impact of Post-Prostatectomy PSA nadir on outcomes&nbsp;&nbsp; following salvage radiotherapy</em>.&nbsp; Urology 1998; 51(6): 998-1002.</p>
<p>&nbsp; &nbsp; &nbsp; &nbsp;<br />2. Guha C, Parashar B, Deb NJ, <strong>Garg MK</strong>, Gorla GR, Singh A, Roy-Chowdhury N, Vikram B, Roy-Chowdhury J: <em>Normal hepatocytes correct serum bilirubin after repopulation of Gunn rat liver subjected to irradiation/partial resection</em>. Hepatology, 2002; 36: 354-62.<br />&nbsp;<br />3. Sood B, <strong>Garg MK</strong>, Avadhani J, Gorla G, Malhotra H, Deore S, Vikram B: <em>Predictive value of Linear Quadratic Model in the treatment of Cervix Cancer using High Dose Rate Brachytherapy. </em>Int J Radiat Oncol Biol Phys 2002; 54(5): 1377-1387.</p>
<p><strong>4. Garg MK</strong>, Yaparpalvi R, Beitler JJ: <em>Loss of Cervical Spinal Curvature during radiation therapy for head and neck cancers. </em>Int J Radiat Oncol Biol Phys 2004; 58(1):185-188.<br />&nbsp;</p>
<p><strong>5.Garg MK, </strong>Beitler JJ:&nbsp; <em>Controversies in management of neck in head and neck cancer. </em>Curr Treat Options Oncol 2004; 5(1): 35-40.<br />&nbsp;</p>
<p><strong>6.Garg MK</strong>, Sharma A, Gorla G, Jaggernauth W, Beitler, JJ: <em>Role of High Dose Rate Brachytherapy in management of Recurrent Keloids after Surgery and External Beam Radiation therapy. </em>Radiother Oncol 2004; 73(2): 233-236.</p>
<p>7. Novetsky A, Einstein M, Goldberg G, Hailpern S, Landau E, Fields A, Mutyala M, Kalnicki S, <strong>Garg MK</strong><em>: </em><em>Efficacy And Toxicity Of Concomitant Cisplatin With External Beam Pelvic Radiotherapy And Two High Dose Rate Brachytherapy Insertions For The Treatment Of Locally-Advanced Cervical Cancer</em>. Radiother Oncol. 2004 Nov;73(2):233-6.</p>
<p>8. Beitler JJ, <strong>Garg MK,</strong> Ahn A, Owen R, Smith R: &ldquo;<em>High Dose Rate (HDR) Brachytherapy plus Neck Dissection for Nodal Disease&rdquo;</em> Head Neck. 2008 Mar 7; [Epub ahead of print]<br />&nbsp;</p>
<p>9. A Mukhopadhaya, J Mendecki, X Dong, L Liu, S Kalnicki, <strong>M Garg,</strong> A Alfieri, C Guha: &ldquo;<em>Localized Hyperthermia Combined with Intratumoral Dendritic Cells Induces Systemic Antitumor Immunity&rdquo;. </em>Cancer Res. 2007 Aug 15;67(16):7798-806.<br />&nbsp;</p>
<p>10. J Belbin, A Bergman, M Brandwein-Gensler, Q Chen, G Childs, <strong>M Garg,</strong> M Haigentz, R Hogue-Angeletti, R Moadel, A Negassa, R Owen, MB Prystowsky¹, B Schiff, NF Schlecht, K Shifteh, RV Smith, X Zheng: <em>&ldquo;Head and Neck Cancer: Reduce and Integrate for Optimal Outcome.&rdquo; </em>Genes Genet Syst. 2007 Oct;82(5):403-8.<br />&nbsp;</p>
<p>11. Peter H. Ahn, MD and <strong>Madhur K. Garg, MD</strong>: &ldquo;<em>PET-CT in head and neck cancers for target delineation</em>.&rdquo; Semin Nucl Med. 2008 Mar;38(2):141-8.<br /><strong>&nbsp;</strong>Yaparpalvi R, Mutyala S, Gorla GR, Butler J, Mah D, <strong>Garg MK</strong>, Kalnicki S. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18782683?ordinalpos=3&amp;itool=Entr… vs. volumetric bladder and rectal doses in combined intracavitary-interstitial high-dose-rate brachytherapy: correlation and comparison with published Vienna applicator data.</a> Brachytherapy. 2008 Oct-Dec;7(4):336-42. Epub 2008 Sep 7.<br />&nbsp;</p>
<p>12. Ahn PH, Ahn AI, Lee CJ, Shen J, Miller E, Lukaj A, Milan E, Yaparpalvi R, Kalnicki S, <strong>Garg MK.</strong> &ldquo;<em><a href="http://www.ncbi.nlm.nih.gov/pubmed/19147027?ordinalpos=1&amp;itool=Entr… positional variation among the skull, mandible, and cervical spine with treatment progression during head-and-neck radiotherapy&rdquo;.</a></em> Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):626-33.<br />&nbsp;</p>
<p>13. Hong LX, Chen CC, <strong>Garg M,</strong> Yaparpalvi R, Mah D. &ldquo;<em><a href="http://www.ncbi.nlm.nih.gov/pubmed/19147020?ordinalpos=2&amp;itool=Entr… experiences with onboard imager KV images for linear accelerator-based stereotactic radiosurgery and radiotherapy setup.</a>&rdquo;</em> Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):556-61.<br />&nbsp;</p>
<p>14. Skinner WK, Muse ED, Yaparpalvi R, Guha C, <strong>Garg MK,</strong> Kalnicki S. <em>&ldquo;<a href="http://www.ncbi.nlm.nih.gov/pubmed/19854386">Obtaining normal tissue constraints using intensity modulated radiotherapy (IMRT) in patients with oral cavity, oropharyngeal, and laryngeal carcinoma.</a></em>&rdquo; Med Dosim. 2009 winter; 34(4):279-84. Epub 2008 Dec 26<br />&nbsp;</p>
<p>15. Lee CC, Wu A, <strong>Garg M,</strong> Mutyala S, Kalnicki S, Sayed G, Mah D <em>&ldquo;<a href="http://www.ncbi.nlm.nih.gov/pubmed/20004563">A new approach to reduce number of split fields in large field IMRT.</a>&rdquo;</em> Med Dosim. [Epub ahead of print]<br />&nbsp;</p>
<p>16. Chen CC, Lee CC, Mah D, Sharma R, Landau E, <strong>Garg M,</strong> Wu A. <em>&ldquo;<a href="http://www.ncbi.nlm.nih.gov/pubmed/20202815">Dose sparing of brainstem and spinal cord for re-irradiating recurrent head and neck cancer with intensity-modulated radiotherapy.</a></em>&rdquo; Med Dosim. 2010 Mar 3. [Epub ahead of print]<br />&nbsp;</p>
<p>17. Quon H, Yom SS, <strong>Garg MK,</strong> Lawson J, McDonald MW, Ridge JA, Saba N, Salama J, Smith R, Yeung AR, Beitler JJ <em>&ldquo;<a href="http://www.ncbi.nlm.nih.gov/pubmed/20541056">ACR Appropriateness Criteria: local-regional therapy for resectable oropharyngeal squamous cell carcinomas.</a></em>&rdquo;Curr Probl Cancer. 2010 May-Jun;34(3):175-92. Review<br />&nbsp;</p>
<p>18. C. R. Salazar, R. V. Smith, <strong>M. Garg,</strong> M. Haigentz Jr., B. Schiff, N. Kawachi, J. Ostoloza, T. J. Belbin, M. B. Prystowsky, R. D. Burk, N. F. Schlecht : <em>&ldquo;Human papillomavirus associated survival and response to therapy in head and neck squamous cell carcinoma&rdquo;</em> Manuscript submitted to Annals of Oncology.<br />&nbsp;</p>
<p>19. Expert Panel on Radiation Oncology-Head and Neck, Salama JK, Saba N, Quon H, <strong>MK</strong> <strong>Garg,</strong> Lawson J, McDonald MW, Ridge JA, Smith RV, Yeung AR, Yom SS, Beitler JJ. <em>ACR appropriateness criteria&reg; adjuvant therapy for resected squamous cell carcinoma of the head and neck.</em> Oral Oncol. 2011 Jul;47(7):554-9. Epub 2011 Jun 12.</p>
<p>20. McDonald MW, Lawson J, <strong>Garg MK,</strong> Quon H, Ridge JA, Saba N, Salama JK, Smith RV, Yeung AR, Yom SS, Beitler JJ; Expert Panel on Radiation Oncology-Head and Neck Cancer. <em>ACR appropriateness criteria retreatment of recurrent head and neck cancer after prior definitive radiation expert panel on radiation oncology-head and neck cancer.</em> Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1292-8. Epub 2011 Apr 27. Review.&nbsp;<br />&nbsp;</p>
<p>21. Hong LX, <strong>Garg M,</strong> Lasala P, Kim M, Mah D, Chen CC, Yaparpalvi R, Mynampati D, Kuo HC, Guha C, Kalnicki S. <em>Experience of micromultileaf collimator linear accelerator based single fraction stereotactic radiosurgery: tumor dose inhomogeneity, conformity, and dose fall off. </em>Med Phys. 2011 Mar;38(3):1239-47</p>
<p>22. Ahn PH, Chen CC, Ahn AI, Hong L, Scripes PG, Shen J, Lee CC, Miller E,Kalnicki S, <strong>Garg MK.</strong> <em>Adaptive planning in intensity-modulated radiation therapy for head and neck cancers: single-institution experience and clinical implications</em>. Int J Radiat Oncol Biol Phys. 2011 Jul 1;80(3):677-85. Epub 2010 Jul 9.</p>
<p>23. Saini G, Aggarwal A, Chomal M, Srivastava R, Sharma PK, Nangia S, Garg M<em>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21981875">Cranio-spinal irradiation with volumetric modulated arc therapy: a multi-institutional treatment experience.</a> </em>Radiother Oncol. 2012 Feb;102(2):322; Epub 2011 Oct 6.</p>
<p>24. Yeung AR, Garg MK, Lawson J, McDonald MW, Quon H, Ridge JA, Saba N, Salama JK, Smith RV, Yom SS, Beitler JJ; <em><a href="http://www.ncbi.nlm.nih.gov/pubmed/22250010">ACR Appropriateness Criteria&reg; ipsilateral radiation for squamous cell carcinoma of the tonsil.</a> </em>Expert Panel on Radiation Oncology--Head &amp; Neck Cancer American College of Radiology. Head Neck. 2012 May;34(5):613-6. doi: 10.1002/hed.21993. Epub 2012 Jan 17.</p>
<p>25. Garg MK, Glanzman J, Kalnicki S. <em><a href="http://www.ncbi.nlm.nih.gov/pubmed/22840597">The evolving role of positron emission tomography-computed tomography in organ-preserving treatment of head and neck cancer.</a> </em>Semin Nucl Med. 2012 Sep;42(5):320-7. doi: 10.1053/j.semnuclmed.2012.04.005. Review.</p>
<p>26. Garg MK, Ridge JA, Yom SS, McDonald MW, Quon H, Smith RV, Yeung AR, Lawson J, Saba N, Salama JK, Beitler JJ. <em>Reply, contralateral irradiation for T(limited)N2bM0 lateralized tonsil cancer.</em> Head Neck. 2013 Mar;35(3):465-6. doi: 10.1002/hed.23212. Epub 2013 Feb 5. No abstract available.<br />&nbsp;</p>
<p>27. Ohri N, Garg MK, Aparo S, Kaubisch A, Tome W, Kennedy TJ, Kalnicki S, Guha C.<em>Who benefits from adjuvant radiation therapy for gastric cancer? A meta-analysis.&nbsp; </em>Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):330-5. doi: 10.1016/j.ijrobp.2013.02.008. Epub 2013 Mar 20. Review.<br />&nbsp;</p>
<p>28. Gez E, Cytron S, Ben Yosef R, London D, Corn BW, Alani S, Scarzello G, Dal Moro F, Sotti G, Zattoni F, Koziol I, Torre T, Bassignani M, Kalnicki S, Ghavamian R, Blakaj D, Anscher M, Sommerauer M, Jocham D, Melchert C, Huttenlocher S, Kovacs G, Garg M. <em>Application of an interstitial and biodegradable balloon system for prostate-rectum separation during prostate cancer radiotherapy: a prospective multi-center study.</em> Radiat Oncol. 2013 Apr 23;8:96. doi: 10.1186/1748-717X-8-96.<br />&nbsp;</p>
<p>29. Mourad WF, Young BM, Young R, Blakaj DM, Orhi N, Shourbaji RA, Manolidis S, G&aacute;mez M, Kumar M, Khorsandi A, Khan MA, Shasha D, Blakaj A, Glanzman J, Garg MK, Hu KS, Kalnicki S, Harrison LB. <em>Clinical validation and applications for CT-based atlas for contouring the lower cranial nerves for head and neck cancer radiation therapy. </em>Oral Oncol. 2013 Sep;49(9):956-63. doi: 10.1016/j.oraloncology.2013.03.449. Epub 2013 Apr 25.<br />&nbsp;</p>
<p>30. Ridge JA, Lawson J, Yom SS, Garg MK, McDonald MW, Quon H, Saba N, Salama JK, Smith RV, Worden F, Yeung AR, Beitler JJ. <em>American College of Radiology Appropriateness Criteria(&reg;) treatment of stage I T1 glottic cancer.</em> Head Neck. 2014 Jan;36(1):3-8. doi: 10.1002/hed.23381. Epub 2013 Sep 18. Review.</p>
<p>31. Einarson TR, Zilbershtein R, Skoup&aacute; J, Vesel&aacute; S, Garg M, Hemels ME. <em>Economic and clinical comparison of atypical depot antipsychotic drugs for treatment of chronic schizophrenia in the Czech Republic. </em>J Med Econ. 2013 Sep;16(9):1089-95. doi: 10.3111/13696998.2013.820193. Epub 2013 Jul 9.&nbsp;<br />&nbsp;</p>
<p>32. Mourad WF, Blakaj DM, Kabarriti R, Young R, Shourbaji RA, Glanzman J, Patel S, Yaparpalvi R, Kalnicki S, Garg MK. <em>Lack of adjuvant radiotherapy may increase risk of retropharyngeal node recurrence in patients with squamous cell carcinoma of the head and neck after transoral robotic surgery.</em> Case Rep Oncol Med. 2013;2013:727904. doi: 10.1155/2013/727904. Epub 2013 Jun 13.<br />&nbsp;</p>
<p>33. Salazar CR, Smith RV, Garg MK, Haigentz M Jr, Schiff BA, Kawachi N, Anayannis N, Belbin TJ, Prystowsky MB, Burk RD, Schlecht NF. <em>Human papillomavirus-associated head and neck squamous cell carcinoma survival: a comparison by tumor site and initial treatment.</em> Head Neck Pathol. 2014 Mar;8(1):77-87. doi: 10.1007/s12105-013-0486-4. Epub 2013 Sep 4.<br />&nbsp;</p>
<p>34. Mourad WF, Young R, Kabarriti R, Blakaj DM, Shourbaji RA, Glanzman J, Patel S, Ohri N, Yaparpalvi R, Beitler JJ, Kalnicki S, Garg MK. <em>25-year follow-up of HIV-positive patients with benign lymphoepithelial cysts of the parotid glands: a retrospective review. </em>Anticancer Res. 2013 Nov;33(11):4927-32.<br />&nbsp;</p>
<p>35. Salazar CR, Anayannis N, Smith RV, Wang Y, Haigentz M Jr, Garg M, Schiff BA, Kawachi N, Elman J, Belbin TJ, Prystowsky MB, Burk RD, Schlecht NF. <em>Combined P16 and human papillomavirus testing predicts head and neck cancer survival. </em>Int J Cancer. 2014 Nov 15;135(10):2404-12. doi: 10.1002/ijc.28876. Epub 2014 Apr 17.<br />&nbsp;</p>
<p>36. Salama JK, Golden DW, Yom SS, Garg MK, Lawson J, McDonald MW, Quon H, Ridge JA, Saba N, Smith RV, Worden F, Yeung AR, Beitler JJ. <em>ACR Appropriateness Criteria&reg; thyroid carcinoma.</em> Oral Oncol. 2014 Jun;50(6):577-86. doi: 10.1016/j.oraloncology.2013.12.004.<br />&nbsp;</p>
<p>37. Kawashita Y, Deb NJ, Garg MK, Kabarriti R, Fan Z, Alfieri AA, Roy-Chowdhury J, Guha C. <em>An autologous in situ tumor vaccination approach for hepatocellular carcinoma. 2. Tumor-specific immunity and cure after radio-inducible suicide gene therapy and systemic CD40-ligand and Flt3-ligand gene therapy in an orthotopic tumor model.</em> Radiat Res. 2014 Aug;182(2):201-10. doi: 10.1667/RR13617.1. Epub 2014 Jul 3.<br />&nbsp;</p>
<p>38. Kawashita Y, Deb NJ, Garg M, Kabarriti R, Alfieri A, Takahashi M, Roy-Chowdhury J, Guha C. <em>An autologous in situ tumor vaccination approach for hepatocellular carcinoma. 1. Flt3 ligand gene transfer increases antitumor effects of a radio-inducible suicide gene therapy in an ectopic tumor model.</em> Radiat Res. 2014 Aug;182(2):191-200. doi: 10.1667/RR13594.1. Epub 2014 Jun 27.<br />&nbsp;</p>
<p>39. Yaparpalvi R, Mehta KJ, Bernstein MB, Kabarriti R, Hong LX, Garg MK, Guha C, Kalnicki S, Tom&eacute; WA. <em>Contouring and constraining bowel on a full-bladder computed tomography scan may not reflect treatment bowel position and dose certainty in gynecologic external beam radiation therapy.</em> Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):802-8. doi: 10.1016/j.ijrobp.2014.07.016. Epub 2014 Sep 20.<br />&nbsp;</p>
<p>40. Kabarriti R, Ohri N, Hannan R, Tishbi N, Baliga S, McGovern KP, Mourad WF, Ghavamian R, Kalnicki S, Guha C, Garg MK. <em>Prostate-specific antigen decline during salvage radiation therapy following prostatectomy is associated with reduced biochemical failure. </em>Pract Radiat Oncol. 2014;4(6):409-14. doi: 10.1016/j.prro.2014.01.002. Epub 2014 Feb 22.<br />&nbsp;</p>
<p>41. Hong LX, Shankar V, Shen J, Kuo HC, Mynampati D, Yaparpalvi R, Goddard L, Basavatia A, Fox J, Garg M, Kalnicki S, Tom&eacute; WA. <em>Spine stereotactic body radiation therapy plans: Achieving dose coverage, conformity, and dose falloff.</em> Med Dosim. 2014 Dec 10. pii: S0958-3947(14)00125-3. doi: 10.1016/j.meddos.2014.11.002. [Epub ahead of print]</p>
<p>42. Ohri N, Rapkin BD, Guha D, Haynes-Lewis H, Guha C, Kalnicki S, Garg M. <em>Predictors of radiation therapy noncompliance in an urban academic cancer center. </em>Int J Radiat Oncol Biol Phys. 2015 Jan 1;91(1):232-8. doi: 10.1016/j.ijrobp.2014.09.030.<br />&nbsp;Ow TJ, Pitts CE, Kabarriti R, Garg MK. <em>Effective Biomarkers and Radiation Treatment in Head and Neck Cancer. </em>Arch Pathol Lab Med. 2015 Jun 5. [Epub ahead of print]</p>
<p>43. Kabarriti R, Mark, D, Garg, MK.<em> Proton therapy for the treatment of pediatric head and neck cancers: a review. </em>J Ped Otorhinolaryng 2105 [in Press]</p>
<p><br />&nbsp;44. Paul B. Romesser, Oren Cahlon,Eli D. Scher, Eugen B. Hug,Kevin Sine, Carl DeSelm, Jana L. Fox, Dennis Mah, Madhur K. Garg, John Han-Chih Chang, and Nancy Y. Lee:<em> &ldquo;Proton Beam Re-Irradiation for Recurrent Head and Neck Cancer: Multi-Institutional Report on Feasibility and Early Outcomes&rdquo;:</em>Int J Radiat Oncol Biol Phys. 2015 (in press)</p>

EMR ID

4254

Biography

<p>Madhur Garg earned his medical degree at King George&rsquo;s Medical College and completed his residency in radiation oncology at Rush-Presbyterian-St. Luke&rsquo;s Hospital in Chicago and Montefiore in New York City. He also completed a specialized fellowship at Wayne State University in Detroit.</p><p>Dr. Garg is the recipient of the prestigious American Society of Clinical Oncology&rsquo;s Young Investigator's Award and the Department of Defense Physician Research Award. He is listed as one of the &ldquo;New York Top Doctors,&rdquo; &ldquo;America&rsquo;s Top Oncologists&rdquo; and &ldquo;Best Doctors in America.&rdquo;</p><p>Dr. Garg serves on several Montefiore and Einstein committees, as well as international societies such as the American Society of Clinical Oncology, the American College of Radiology and the American Society for Radiation Oncology. He is on the review boards for several journals, including <em>International Journal of Radiation Oncology &bull; Biology &bull; Physics</em>.</p>

Is Open Scheduling

Off